Genetic risk models and variant classification tools are refining breast cancer risk assessment by identifying high-risk individuals for intensive surveillance or targeted therapies, while guiding ...
Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma Next-generation sequencing ...
SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA), a genetic information company, today presented an important study at the 2016 American College of Medical Genetics and Genomics (ACMG) ...
Please provide your email address to receive an email when new articles are posted on . Researchers assigned clinical classifications to thousands of BRCA2 variants of uncertain significance. Research ...
SAN FRANCISCO, March 12, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company, today announced the launch of an update to Invitae Generation™ with Clinical Variant Modeling, a ...
In a recent study published in Nature Genetics, researchers performed saturation genome editing (SGE) of the BRCA1-associated protein-1 gene (BAP1), whose dysfunction is related to cancer and impaired ...
The partnership between OGT and QIAGEN Digital Insights (QDI), expands OGT’s bioinformatics capabilities by integrating QIAGEN’s advanced tertiary analysis solution, QCI Interpret, with its SureSeq™ ...
While the delta COVID-19 variant is the dominant strain in the U.S., it’s now officially the dominant strain worldwide “by far,” officials from the World Health Organization said during a Sept. 21 ...
The XFG variant of the severe acute respiratory syndrome coronavirus 2 as continued to spread as the U.S. heads into peak Summer travel season. (Photo by I RYU/VCG via Getty Images) There’s another ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback